Clearmind Medicine Inc.

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of novel psychedelic-derived and neuroplastogen-derived therapeutics. The company's core mission is to address widespread and underserved health problems, with a primary focus on conditions such as alcohol use disorder. Headquartered in Vancouver, British Columbia, Canada, Clearmind Medicine operates with a commitment to advancing innovative treatments in the mental health and addiction space.

The company's key product pipeline includes CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound, which is currently in Phase I/IIa clinical trials for the treatment of Alcohol Use Disorder (AUD). Beyond AUD, Clearmind Medicine is also developing treatments for binge drinking, eating disorders, obesity, and metabolic disorders, and is exploring an alcohol substitute consumer product. The company's research and development efforts are centered on commercializing psychedelic-based compounds as regulated medicines, foods, or supplements.

Clearmind Medicine is actively engaged in multinational Phase I/IIa clinical trials for CMND-100, with prominent sites including Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. The company has reported successful completion of treatment for Part A and the second cohort of its FDA-approved trial, demonstrating progress in its clinical development. Dr. Adi Zuloff-Shani serves as the Chief Executive Officer, and Hila Kiron-Revach was appointed chairperson of the board in April 2026. Clearmind Medicine maintains a robust intellectual property portfolio, comprising nineteen patent families and 31 granted patents, underscoring its market positioning as an innovator in psychedelic medicine.